Depomed acquires US and Canadian rights to Lazanda for Cancer Pain
Depomed, Inc. announced that it has acquired all United States and Canadian rights to Lazanda (fentanyl) nasal spray from Archimedes Pharma Limited.
Lazanda is indicated for the management of Breakthrough Cancer Pain for patients (BTPc) 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Lazanda was introduced by Archimedes in Europe in 2010 under the trade name PecFent and in the United States in 2011. Depomed acquired all United States and Canadian rights to the product in return for $4 million of cash, royalties on net sales, potential milestone payments based on increased sales of Lazanda and assumption of certain liabilities. According to Source Healthcare Analytics, sales of Lazanda in the U.S. were $3.3 million for the 12 months ended June 30, 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins